Text this: Efficacy and safety of first-line necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in East Asian patients with stage IV squamous non-small cell lung cancer: A subgroup analysis of the phase 3, open-label, randomized SQUIRE study

  ______    _____    _    _      ___      _____   
 /_   _//  |  ___|| | |  | ||   / _ \\   |__  //  
 `-| |,-   | ||__   | |/\| ||  | / \ ||    / //   
   | ||    | ||__   |  /\  ||  | \_/ ||   / //__  
   |_||    |_____|| |_// \_||   \___//   /_____|| 
   `-`'    `-----`  `-`   `-`   `---`    `-----`